Dihydroquinazolin-4(1H)-ones
1969
Typical Experimental Procedure
Isatoic anhydride (1 mmol), aniline (1.2 mmol), benzaldehyde (1 mmol), and
Amberlyst-15 (80 mg) were put in a 25-ml, round-bottom flask. The reaction
mixture was stirred at room temperature with the help of a magnetic stirrer.
The flask was kept in the domestic microwave oven, and the contents were
irradiated with microwaves at 360 W, with irradiation pulses of 1 min each
followed by a cooling period of 30 s at room temperature after every pulse.
After the completion of the reaction (as indicated on TLC), the reaction
mixture was cooled to room temperature, and hot ethanol (10 ml) was
added. The reaction mixture was filtered using a G-3 filter to separate the
catalyst. The filtrate was concentrated under vacuum to obtain the solid
product. The product was crystallized from absolute alcohol. To study the
recyclability of the catalyst, the catalyst was isolated after each run, washed
with hot ethanol, and dried at 1008C for 6 h.
REFERENCES
1. (a) Hamel, E.; Lin, C. M.; Plowman, J.; Wang, H.; Lee, K.; Paull, K. D. Biochem.
Pharmacol. 1996, 51, 53; (b) Biressi, M. G.; Cantarelli, G.; Carissimi, M.;
Catteneo, A.; Ravenna. Ed. Sci. 1969, 24, 199; (c) Bhalla, P. R.;
Walworth, B. L. Chem. Abstr. 1983, 98, 1669; (d) Bhalla, P. R. Walworth, B. L.
Chem. Abstr. 1984, 100, 174857; (e) Hour, M.; Huang, L.; Kuo, S.; Xia, Y.;
Bastow, K.; Nakanishi, Y.; Hamel, E.; Lee, K. 6-Alkylamino- and 2,3-dihydro-
30-methoxy-2-phenyl-4-quinazolinones and related compounds: Their synthesis,
cytotoxicity and inhibition of tubilin polymerization. J. Med. Chem. 2000, 43,
4479–4487.
2. (a) Rao, V. B.; Hanumanthu, P.; Ratnam, C. V. Indian J. Chem. 1979, 18B, 493;
(b) Lopez, S. E.; Rosales, M. E.; Urdaneta, N.; Godoy, M. V.; Charris, J. E.
J. Chem. Res., Synop. 2000, 258; (c) Abdel-Jalil, R. J.; Volter, W.; Saeed, M. A
novel method for the synthesis of 4(3H)quinazolinone. Tetrahedron Lett. 2004,
45, 3475–3478.
3. (a) Wolf, J. F.; Rathman, T. L.; Sleevi, M. C.; Campbell, J. A.; Greenwood, T. D.
Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-qui-
nazolinones. J. Med. Chem. 1990, 33, 161–166; (b) Padia, J. K.; Field, M.;
Hinton, J.; Meecham, K.; Pablo, J.; Pinnock, R.; Roth, B. D.; Singh, L.; Suman-
Chauhan, N.; Trivedi, B. K.; Webdale, L. Novel non-peptide CCK-B antagonists:
Design and development of quinazolinone derivatives as potent, selective, and
orally active CCK-B antagonists. J. Med. Chem. 1998, 41, 1042–1049;
(c) Kung, P.-P.; Casper, M. D.; Cook, K. L.; Wilson-Lingard, L.; Risen, L. M.;
Vickers, T. A.; Ranken, R.; Blyn, L. B.; Wyatt, R.; Cook, P. D.; Ecker, D. J.
Structure–Activity relationship of novel 2-substituted quinazoline antibacterial
agents. J. Med. Chem. 1999, 42, 4705–4713; (d) Tsou, H.-R.; Mamuya, N.;
Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Y.-F.; Wissner, A. 6-Substituted-4-
(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the
epidermal growth factor receptor(EFGR) and human epidermal growth factor
receptor (HER-2) tyrosine kinases with enhanced anti-tumour activity. J. Med.